Single-session radiosurgery for Cushing disease after failed resection: a retrospective single-center cohort study.

Authors

Bardia Hajikarimloo, Salem M Tos, Yuki Shinya, Onam Verma, Evan Mancini, Sean Morgan, Zhenye Li, Georgios Mantziaris, Gregory K Hong, Jason P Sheehan

Published in

The Journal of clinical endocrinology and metabolism. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

Cushing disease (CD) from an adrenocorticotropic hormone-secreting pituitary adenoma causes substantial morbidity when hypercortisolism persists or recurs after transsphenoidal surgery (TSS).
To define endocrine control, radiographic response, toxicity, and predictors after single-session Gamma Knife radiosurgery for residual or recurrent CD.
Retrospective single-center cohort study, 1990-2026; median endocrine follow-up 54 months.
Single academic tertiary referral center.
186 adults with residual or recurrent CD after ≥1 TSS and ≥12 months of follow-up. Median age 40.8 years; 78.0% female.
Single-session frame-based SRS (median prescription dose 23.0 Gy; maximum dose 48.0 Gy).
Prespecified primary outcome was durable biochemical control off medications (sustained 24-hour urinary free cortisol [UFC] normalization without cortisol-lowering therapy), modeled with competing-risks methodology.
UFC normalized in 152 patients (81.7%), including 134 (72.0%) off all medications. Cumulative incidence of durable off-medication control was 51% (95% CI: 44-58%) at 12 months and 64% (95% CI: 56-71%) at 120 months. New endocrinopathy reached 42% (95% CI: 32-52%) at 120 months; new visual deficit occurred in 3.2%. A TSS-to-SRS interval <6 months independently predicted higher durable control (P < .001), while higher baseline AM cortisol (P < .001), whole-sella treatment (P = .013), and female gender (P = .027) predicted lower durable control. Higher maximum dose was the sole independent predictor of new endocrinopathy (P = .009).
Single-session SRS achieves durable medication-free control in approximately two-thirds of patients with residual or recurrent CD, with excellent tumor control and meaningful delayed endocrine toxicity warranting long-term surveillance.

PMID:
43006778
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.